Red blood cell transfusions for thalassemia: Results of a survey assessing current practice and proposal of evidence-based guidelines

Transfusion

Volumn 54, Issue 7, 2014, Pages 1773-1781

  Goss, Cheryl ^a   Giardina, Patricia ^a   Degtyaryova, Diana ^a   Kleinert, Dorothy ^a   Sheth, Sujit ^a   Cushing, Melissa ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIBODY; ERYTHROCYTE ANTIGEN;

ADULT; CLINICAL PRACTICE; CONTROLLED STUDY; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; GENOTYPE; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRACTICE GUIDELINE; QUESTIONNAIRE; REVIEW; THALASSEMIA MAJOR; TRANSFUSION MEDICINE; VERBAL COMMUNICATION;

BLOOD PRESERVATION; BLOOD SAFETY; DATA COLLECTION; ERYTHROCYTE TRANSFUSION; EVIDENCE-BASED PRACTICE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; QUESTIONNAIRES; THALASSEMIA; UNITED STATES;

EID: 84904504434     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12571     Document Type: Review

References (47)

1. Modell B, Darlison M,. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487.
2. Weatherall DJ,. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331-4336.
3. Piomelli S, Danoff SJ, Becker MH, et al. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen. Ann N Y Acad Sci 1969; 165: 427-436.
4. Schorr JB, Radel E,. Transfusion therapy and its complications in patients with Cooley's anemia. Ann N Y Acad Sci 1964; 119: 703-708.
5. Wolman IJ,. Transfusion therapy in Cooley's anemia: growth and health as related to long-range hemoglobin levels. A progress report. Ann N Y Acad Sci 1964; 119: 736-747.
6. Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia. 2nd revised edition. 2008 [cited 2013 Jul 16]. Available from: http://www.thalassaemia.org.cy
7. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992; 117: 151-162.
8. Dzik S, Aubuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000; 14: 34-52.
9. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44: 25-29.
10. Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42: 1114-1122.
11. Hébert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289: 1941-1949.
12. Sirchia G, Rebulla P, Parravicini A, et al. Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion 1987; 27: 402-405.
13. Sirchia G, Wenz B, Rebulla P, et al. Removal of white cells from red cells by transfusion through a new filter. Transfusion 1990; 30: 30-33.
14. Reverberi R, Ferrari L, Gennari M, et al. Prevention of non-hemolytic transfusion reactions with leucocyte-poor blood: a prospective study. Haematologica 1989; 74: 283-288.
15. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-3603.
16. Wu Y, Zou S, Cable R, et al. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010; 50: 776-786.
17. Thiele T, Krüger W, Zimmermann K, et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51: 2620-2626.
18. Roback JD, Conlan M, Drew WL, et al. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006; 20: 45-56.
19. Tegtmeier GE,. Posttransfusion cytomegalovirus infections. Arch Pathol Lab Med 1989; 113: 236-245.
20. Weisbach V, Riego W, Strasser E, et al. The in vitro quality of washed, prestorage leucocyte-depleted red blood cell concentrates. Vox Sang 2004; 87: 19-26.
21. MacoProductions S.A.S. NDA 040083 Summary for basis of approval. 2004. [cited 2013 Jul 16]. Available from: http://www.fda.gov/downloads/ biologicsbloodvaccines/bloodbloodproducts/approvedproducts/ newdrugapplicationsndas/ucm082811.pdf
22. Haemonetics Corporation. Haemonetics Additive Solution Formula 3 (AS-3). 2013 [cited 2013 Jul 16]. Available from: http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=e6775fa2-9f23-4d71-be07-1e9e4d6265d0
23. Terumo Corporation. Blood bag system anticoagulant citrate phosphate dextrose adenine (CPDA-1). 2012. [cited 2013 Jul 16]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b53ad8-3e44-401e-bd9b- ca81848a6b18
24. Terumo Corporation. Teruflex blood bag system with diversion blood sampling arm anticoagulant CPD and Optisol (AS-5) red cell preservative. 2011. [cited 2013 Jul 16]. Available from: http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=2546f700-3df3-4b14-b3c6-901cd6262774
25. Kakaiya R, Aronson C, Julleis J,. Whole blood collection and component processing at blood collection centers. In:, Roback J, editor. Technical manual. 17th ed. Bethesda (MD): American Association of Blood Banks; 2011. p. 187-226.
26. Wang D, Sun J, Solomon SB, et al. Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion 2012; 52: 1184-1195.
27. Callan MB, Patel RT, Rux AH, et al. Transfusion of 28-day-old leucoreduced or non-leucoreduced stored red blood cells induces an inflammatory response in healthy dogs. Vox Sang 2013; 105: 319-327.
28. Hod EA, Zhang N, Sokol SA, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood 2010; 115: 4284-4292.
29. Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood 2011; 118: 6675-6682.
30. Hult A, Malm C, Oldenborg PA,. Transfusion of cryopreserved human red blood cells into healthy humans is associated with rapid extravascular hemolysis without a proinflammatory cytokine response. Transfusion 2013; 53: 28-33.
31. Thompson AA, Cunningham MJ, Singer ST, et al.; Thalassemia Clinical Research Network Investigators. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011; 153: 121-128.
32. Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58: 50-55.
33. Guirat-Dhouib N, Mezri M, Hmida H, et al. High frequency of autoimmunization among transfusion-dependent Tunisian thalassaemia patients. Transfus Apher Sci 2011; 45: 199-202.
34. Saied DA, Kaddah AM, Badr Eldin RM, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent Egyptian thalassemic patients. J Pediatr Hematol Oncol 2011; 33: 409-414.
35. Arinsburg SA, Skerrett DL, Kleinert D, et al. The significance of a positive DAT in thalassemia patients. Immunohematology 2010; 26: 87-91.
36. Tovo PA, Miniero R, Barbera C, et al. Serum immunoglobulins in homozygous beta-thalassemia. Acta Haematol 1981; 65: 21-25.
37. Garratty G,. The significance of IgG on the red cell surface. Transfus Med Rev 1987; 1: 47-57.
38. American Association of Blood Banks. Standards for blood banks and transfusion services. 28th ed. Bethesda (MD): American Association of Blood Banks; 2012.
39. Galel SA,. Infectious disease screening. In:, Roback JD, editor. Technical manual. Bethesda (MD): American Association of Blood Banks; 2011. p. 239-270.
40. Dodd RY,. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159: 135-142.
41. Seltsam A, Müller TH,. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162: 442-454.
42. Piomelli S, Karpatkin MH, Arzanian M, et al. Hypertransfusion regimen in patients with Cooley's anemia. Ann N Y Acad Sci 1974; 232: 186-192.
43. Pasricha SR, Frazer DM, Bowden DK, et al. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood 2013; 122: 124-133.
44. Taher AT, Musallam KM, Karimi M, et al. Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Rev 2012; 26 (Suppl 1): S24-27.
45. Tobian AA, King KE, Ness PM,. Prevention of febrile nonhemolytic and allergic transfusion reactions with pretransfusion medication: is this evidence-based medicine? Transfusion 2008; 48: 2274-2276.
46. Kennedy LD, Case LD, Hurd DD, et al. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion 2008; 48: 2285-2291.
47. Verster JC, Volkerts ER,. Antihistamines and driving ability: evidence from on-The-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004; 92: 294-303; quiz 303-5, 355.